X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs MERCK LTD - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA MERCK LTD ABBOTT INDIA/
MERCK LTD
 
P/E (TTM) x 36.8 44.1 83.3% View Chart
P/BV x 9.5 6.4 147.0% View Chart
Dividend Yield % 0.7 0.5 138.3%  

Financials

 ABBOTT INDIA   MERCK LTD
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
MERCK LTD
Dec-17
ABBOTT INDIA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs6,1101,358 450.1%   
Low Rs3,996933 428.3%   
Sales per share (Unadj.) Rs1,552.2665.0 233.4%  
Earnings per share (Unadj.) Rs188.856.6 333.7%  
Cash flow per share (Unadj.) Rs196.472.5 271.0%  
Dividends per share (Unadj.) Rs55.0015.00 366.7%  
Dividend yield (eoy) %1.11.3 83.1%  
Book value per share (Unadj.) Rs796.6441.7 180.3%  
Shares outstanding (eoy) m21.2516.60 128.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.31.7 189.0%   
Avg P/E ratio x26.820.2 132.2%  
P/CF ratio (eoy) x25.715.8 162.8%  
Price / Book Value ratio x6.32.6 244.7%  
Dividend payout %29.126.5 109.9%   
Avg Mkt Cap Rs m107,37619,011 564.8%   
No. of employees `0003.31.5 215.2%   
Total wages/salary Rs m3,9371,696 232.1%   
Avg. sales/employee Rs Th9,929.37,150.0 138.9%   
Avg. wages/employee Rs Th1,185.11,098.7 107.9%   
Avg. net profit/employee Rs Th1,207.7608.2 198.6%   
INCOME DATA
Net Sales Rs m32,98511,040 298.8%  
Other income Rs m1,170240 488.1%   
Total revenues Rs m34,15511,279 302.8%   
Gross profit Rs m5,2451,376 381.1%  
Depreciation Rs m162264 61.3%   
Interest Rs m380-   
Profit before tax Rs m6,2151,352 459.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0170 0.0%   
Tax Rs m2,203583 378.0%   
Profit after tax Rs m4,012939 427.2%  
Gross profit margin %15.912.5 127.6%  
Effective tax rate %35.443.1 82.2%   
Net profit margin %12.28.5 143.0%  
BALANCE SHEET DATA
Current assets Rs m22,6557,523 301.1%   
Current liabilities Rs m6,6812,253 296.6%   
Net working cap to sales %48.447.7 101.4%  
Current ratio x3.43.3 101.5%  
Inventory Days Days6552 124.2%  
Debtors Days Days2941 71.9%  
Net fixed assets Rs m8351,240 67.4%   
Share capital Rs m213166 128.0%   
"Free" reserves Rs m16,7157,167 233.2%   
Net worth Rs m16,9287,333 230.9%   
Long term debt Rs m00-   
Total assets Rs m24,1629,912 243.8%  
Interest coverage x163.7NM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.41.1 122.6%   
Return on assets %16.89.5 176.9%  
Return on equity %23.712.8 185.1%  
Return on capital %36.920.8 178.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3691,015 36.3%   
Fx outflow Rs m3,8073,043 125.1%   
Net fx Rs m-3,438-2,028 169.5%   
CASH FLOW
From Operations Rs m1,527537 284.6%  
From Investments Rs m-2,148-476 451.1%  
From Financial Activity Rs m-1,024-220 466.0%  
Net Cashflow Rs m-1,646-160 1,031.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 51.8 144.8%  
Indian inst/Mut Fund % 7.9 18.2 43.4%  
FIIs % 0.1 1.0 10.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 29.1 58.8%  
Shareholders   18,270 28,591 63.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   AUROBINDO PHARMA  ORCHID PHARMA LTD  NOVARTIS  J.B.CHEMICALS  SHASUN PHARMA  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

MERCK LTD Announces Quarterly Results (2QFY19); Net Profit Up 29.8% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, MERCK LTD has posted a net profit of Rs 411 m (up 29.8% YoY). Sales on the other hand came in at Rs 2 bn (down 27.7% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

Are Foreign Investors Heading Back to the Indian Stock Markets?(Chart Of The Day)

Dec 3, 2018

After months of heavy FII selling, November witnessed a return on foreign money into Indian equities...

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Dec 14, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS